Search Results for "Screening"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Screening. Results 11 to 20 of 136 total matches.
Rescheduling of Hydrocodone Combination Products
The Medical Letter on Drugs and Therapeutics • Oct 13, 2014 (Issue 1453)
-2769
The FDA has approved Cologuard (Exact Sciences),
a stool DNA test, to screen average-risk adults ...
The Drug Enforcement Administration (DEA) has
reclassified all hydrocodone combination products
as schedule II controlled substances; they were
previously classified as schedule III. Hydrocodone
alone (Zohydro ER) is already a schedule II controlled
substance.
PSA Reconsidered
The Medical Letter on Drugs and Therapeutics • Aug 06, 2012 (Issue 1396)
more on the contentious question of whether men
should be screened for prostate cancer by measuring ...
Three recent publications have focused attention once
more on the contentious question of whether men
should be screened for prostate cancer by measuring
serum concentrations of prostate specific antigen (PSA).
Virtual Colonoscopy
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005 (Issue 1202)
Publication
Virtual colonoscopy (VC) is less invasive than optical
colonoscopy in screening for colorectal ...
Currently available techniques for colorectal cancer screening include fecal occult-blood testing, flexible sigmoidoscopy, double contrast barium enema (DCBE) and traditional optical colonoscopy. Optical colonoscopy requires bowel cleansing and sedation, and involves some risk, but is generally accepted as the best available method for detection of lesions and offers the advantage that polyps can be removed when they are identified. A less invasive screening tool, computed tomography (CT) colonography, also known as virtual colonoscopy (VC), offers an additional option.
In Brief: Testing for Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
were screened
with TVUS annually from 1987 to 2005, 364 patients
had exploratory surgery, and 44 had ...
Recent publicity about symptoms of ovarian cancer will prompt many questions from patients about testing for the disease. Early-stage epithelial ovarian cancer is potentially curable, with survival rates of 90-95%, but about 75% of women have advanced or metastatic disease at diagnosis. Between physical examination and exploratory surgery, 2 tests are commonly used.1Transvaginal ultrasound (TVUS) images the ovaries better than transabdominal ultrasound. In a study in which 25,327 asymptomatic women were screened with TVUS annually from 1987 to 2005, 364 patients had exploratory surgery, and 44...
CT Colonography (Virtual Colonoscopy) Revisited
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
: 800-211-2769
CT Colonography (Virtual Colonoscopy)
Revisited
Options in screening for colon cancer ...
Options in screening for colon cancer include fecal occult blood tests, flexible sigmoidoscopy, colonoscopy, computed tomography (CT) colonography and fecal DNA tests. Since the last Medical Letter article on this subject, more data have become available on colonography.
Prostate Specific Antigen
The Medical Letter on Drugs and Therapeutics • Oct 02, 1992 (Issue 880)
screening is
a matter of controversy; it is currently approved by the US Food and Drug Administration (FDA ...
Serum measurements of prostate specific antigen (PSA) are now being used in the diagnosis and management of prostate cancer. Produced by prostatic epithelium, PSA is a protease involved in liquefaction of the seminal coagulum. Whether this test should be used for routine screening is a matter of controversy; it is currently approved by the US Food and Drug Administration (FDA) only for monitoring after treatment for prostate cancer.
Omalizumab (Xolair) for Chronic Urticaria
The Medical Letter on Drugs and Therapeutics • May 27, 2013 (Issue 1417)
10801 • A Nonprofit Publication
Breast Cancer Screening
Some Medical Letter readers may want ...
Omalizumab (Xolair) is a recombinant humanized
monoclonal anti-IgE antibody currently approved by
the FDA for treatment of moderate to severe persistent
allergic asthma. It has been used off-label for treatment
of allergic rhinitis and food allergies. Recently the
results of a phase III clinical trial indicated that omalizumab
may be effective in treating chronic urticaria as
well.
Sapropterin (Kuvan) for Phenylketonuria
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
function.
CLINICAL STUDIES — In an uncontrolled screening
study, 489 patients with PKU who were 8-48 ...
Sapropterin (Kuvan - BioMarin) has been approved by the FDA to reduce phenylalanine plasma concentrations in patients with phenylketonuria (PKU). PKU is a rare genetic disorder (it occurs in 1 in 8000 Caucasian and 1 in 50,000 African-American newborns) caused by a deficiency of phenylalanine hydroxylase (PAH) the resulting high levels of the amino acid in blood and urine lead to cognitive, behavioral and other neurological complications.
Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
as no evidence of illicit opioid use in at least
2 of 3 screenings in weeks 9-11, at week 12, and in at least 5 ...
The FDA has approved a subcutaneously injected,
extended-release formulation of the mu-opioid
receptor partial agonist and kappa-opioid receptor
antagonist buprenorphine (Brixadi – Braeburn)
for once-weekly or once-monthly treatment of
moderate to severe opioid use disorder. Brixadi is
the second subcutaneously injected buprenorphine
formulation to be approved in the US; Sublocade,
which is administered once monthly, was the first.
Buprenorphine is also available for treatment of
opioid use disorder in sublingual formulations with
and without the opioid antagonist...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 doi:10.58347/tml.2023.1683c | Show Introduction Hide Introduction
Correction: Plenvu
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
be taken as two doses in a single day or split over two days.
bowel preparation cancer screening ...
In our article in issue 1564 on Plenvu for colonoscopy preparation (Med Lett Drugs Ther 2019; 61:11), the comparator drug in the DAYB trial was not Prepopik, but rather Citrafleet, a similar sodium picosulfate-based preparation that is not available in the US. Also, we said that Plenvu can be taken as a single- or split-dose regimen; we should have said that it can be taken as two doses in a single day or split over two days.